Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in J Am Coll Cardiol

Retrieve available abstracts of 45 articles:
HTML format

Single Articles

    August 2022
  1. MOHEBI R, Chen C, Ibrahim NE, McCarthy CP, et al
    Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates.
    J Am Coll Cardiol. 2022;80:565-578.
    PubMed     Abstract available

    June 2022
  2. DOI T, Langsted A, Nordestgaard BG
    Elevated Remnant Cholesterol Reclassifies Risk of Ischemic Heart Disease and Myocardial Infarction.
    J Am Coll Cardiol. 2022;79:2383-2397.
    PubMed     Abstract available

  3. HAUGE MG, Damm P, Kofoed KF, Ersboll AS, et al
    Early Coronary Atherosclerosis in Women With Previous Preeclampsia.
    J Am Coll Cardiol. 2022;79:2310-2321.
    PubMed     Abstract available

    May 2022
  4. STUART JJ, Tanz LJ, Rimm EB, Spiegelman D, et al
    Cardiovascular Risk Factors Mediate the Long-Term Maternal Risk Associated With Hypertensive Disorders of Pregnancy.
    J Am Coll Cardiol. 2022;79:1901-1913.
    PubMed     Abstract available

  5. GABA P, Bhatt DL, Steg PG, Miller M, et al
    Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
    J Am Coll Cardiol. 2022;79:1660-1671.
    PubMed     Abstract available

    March 2022
  6. HOVINGH GK, Klausen IC, Heggen E, McCarty K, et al
    Resmetirom (MGL-3196) in Patients With Heterozygous Familial Hypercholesterolemia.
    J Am Coll Cardiol. 2022;79:1220-1222.

  7. SNIDERMAN AD, Glavinovic T, Thanassoulis G
    Key Questions About Familial Hypercholesterolemia: JACC Review Topic of the Week.
    J Am Coll Cardiol. 2022;79:1023-1031.
    PubMed     Abstract available

    January 2022
  8. SINGH N, Bhatt DL, Miller M, Steg PG, et al
    Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT.
    J Am Coll Cardiol. 2022;79:220-222.

    November 2021
  9. BRANDTS J, Ray KK
    Familial Hypercholesterolemia: JACC Focus Seminar 4/4.
    J Am Coll Cardiol. 2021;78:1831-1843.
    PubMed     Abstract available

  10. ROSENSON RS, Shaik A, Song W
    New Therapies for Lowering Triglyceride-Rich Lipoproteins: JACC Focus Seminar 3/4.
    J Am Coll Cardiol. 2021;78:1817-1830.
    PubMed     Abstract available

    October 2021
  11. TALASAZ AH, Sadeghipour P, Aghakouchakzadeh M, Dreyfus I, et al
    Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review.
    J Am Coll Cardiol. 2021;78:1635-1654.
    PubMed     Abstract available

  12. DZAYE O, Razavi AC, Dardari ZA, Shaw LJ, et al
    Modeling the Recommended Age for Initiating Coronary Artery Calcium Testing Among At-Risk Young Adults.
    J Am Coll Cardiol. 2021;78:1573-1583.
    PubMed     Abstract available

  13. GABA P, Bhatt DL, Giugliano RP, Steg PG, et al
    Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
    J Am Coll Cardiol. 2021;78:1525-1537.
    PubMed     Abstract available

  14. OLEAGA C, Shapiro MD, Hay J, Mueller PA, et al
    Hepatic Sensing Loop Regulates PCSK9 Secretion in Response to Inhibitory Antibodies.
    J Am Coll Cardiol. 2021;78:1437-1449.
    PubMed     Abstract available

    August 2021
  15. VIRANI SS, Morris PB, Agarwala A, Ballantyne CM, et al
    2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee.
    J Am Coll Cardiol. 2021;78:960-993.

    July 2021
  16. AHMAD Z, Pordy R, Rader DJ, Gaudet D, et al
    Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia.
    J Am Coll Cardiol. 2021;78:193-195.

    June 2021
  17. RAPOSEIRAS-ROUBIN S, Rossello X, Oliva B, Fernandez-Friera L, et al
    Triglycerides and Residual Atherosclerotic Risk.
    J Am Coll Cardiol. 2021;77:3031-3041.
    PubMed     Abstract available

  18. LOPEZ-SAINZ A, Mila L, Rodriguez-Palomares J, Limeres J, et al
    Aortic Branch Aneurysms and Vascular Risk in Patients With Marfan Syndrome.
    J Am Coll Cardiol. 2021;77:3005-3012.
    PubMed     Abstract available

  19. SABATINE MS, Braunwald E
    Thrombolysis In Myocardial Infarction (TIMI) Study Group: JACC Focus Seminar 2/8.
    J Am Coll Cardiol. 2021;77:2822-2845.
    PubMed     Abstract available

    March 2021
  20. TSIMIKAS S, Moriarty PM, Stroes ES
    Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2/4.
    J Am Coll Cardiol. 2021;77:1576-1589.
    PubMed     Abstract available

  21. NURMOHAMED NS, Navar AM, Kastelein JJP
    New and Emerging Therapies for Reduction of LDL-Cholesterol and Apolipoprotein B: JACC Focus Seminar 1/4.
    J Am Coll Cardiol. 2021;77:1564-1575.
    PubMed     Abstract available

  22. JOHANNESEN CDL, Mortensen MB, Langsted A, Nordestgaard BG, et al
    Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.
    J Am Coll Cardiol. 2021;77:1439-1450.
    PubMed     Abstract available

  23. WRIGHT RS, Ray KK, Raal FJ, Kallend DG, et al
    Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis.
    J Am Coll Cardiol. 2021;77:1182-1193.
    PubMed     Abstract available

    February 2021
  24. PERAKAKIS N, Farr OM, Mantzoros CS
    Leptin in Leanness and Obesity: JACC State-of-the-Art Review.
    J Am Coll Cardiol. 2021;77:745-760.
    PubMed     Abstract available

  25. CICERO AFG, Fogacci F, Zambon A
    Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar.
    J Am Coll Cardiol. 2021;77:620-628.
    PubMed     Abstract available

    January 2021
  26. PIETRI P, Stefanadis C
    Cardiovascular Aging and Longevity: JACC State-of-the-Art Review.
    J Am Coll Cardiol. 2021;77:189-204.
    PubMed     Abstract available

    December 2020
  27. GHOSHHAJRA BB, Foldyna B, Gaudet D, Khoury E, et al
    Coronary Atheroma Regression From Infusions of Autologous Selectively Delipidated Prebeta-HDL-Enriched Plasma in Homozygous Familial Hypercholesterolemia.
    J Am Coll Cardiol. 2020;76:3062-3064.

  28. CASTANER O, Pinto X, Subirana I, Amor AJ, et al
    Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease.
    J Am Coll Cardiol. 2020;76:2712-2724.
    PubMed     Abstract available

  29. KRISHNASWAMI A, Beavers C, Dorsch MP, Dodson JA, et al
    Gerotechnology for Older Adults With Cardiovascular Diseases: JACC State-of-the-Art Review.
    J Am Coll Cardiol. 2020;76:2650-2670.
    PubMed     Abstract available

    November 2020
  30. BHATT DL, Budoff MJ, Mason RP
    A Revolution in Omega-3 Fatty Acid Research.
    J Am Coll Cardiol. 2020;76:2098-2101.

    October 2020
  31. MECHANICK JI, Rosenson RS, Pinney SP, Mancini DM, et al
    Coronavirus and Cardiometabolic Syndrome: JACC Focus Seminar.
    J Am Coll Cardiol. 2020;76:2024-2035.
    PubMed     Abstract available

    September 2020
  32. BOCCARA F, Rosenson RS
    Reply: Role of Ezetimibe in the Current Era in Treating Dyslipidemia in HIV-Infected Patients.
    J Am Coll Cardiol. 2020;76:1503-1504.

  33. SINGH A, Mittal S, Kazimuddin M
    Role of Ezetimibe in the Current Era in Treating Dyslipidemia in HIV-Infected Patients.
    J Am Coll Cardiol. 2020;76:1503.

  34. ROSENSON RS, Colantonio LD, Goonewardena SN
    Optimizing Cholesterol Management Improves the Benefits of Percutaneous Coronary Intervention.
    J Am Coll Cardiol. 2020;76:1451-1454.

    July 2020
    PCSK9 Inhibitors for Homozygous Familial Hypercholesterolemia: Useful But Seldom Sufficient.
    J Am Coll Cardiol. 2020;76:143-145.

  36. BLOM DJ, Harada-Shiba M, Rubba P, Gaudet D, et al
    Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
    J Am Coll Cardiol. 2020;76:131-142.
    PubMed     Abstract available

    June 2020
  37. TOTH PP
    Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds Them.
    J Am Coll Cardiol. 2020;75:2694-2697.

  38. TRINDER M, DeCastro ML, Azizi H, Cermakova L, et al
    Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia.
    J Am Coll Cardiol. 2020;75:2682-2693.
    PubMed     Abstract available

    May 2020
  39. KASTELEIN JJP, Reeskamp LF, Hovingh GK
    Familial Hypercholesterolemia: The Most Common Monogenic Disorder in Humans.
    J Am Coll Cardiol. 2020;75:2567-2569.

  40. BEHESHTI SO, Madsen CM, Varbo A, Nordestgaard BG, et al
    Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.
    J Am Coll Cardiol. 2020;75:2553-2566.
    PubMed     Abstract available

  41. BOCCARA F, Kumar PN, Caramelli B, Calmy A, et al
    Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study.
    J Am Coll Cardiol. 2020;75:2570-2584.
    PubMed     Abstract available

  42. BHATT DL, Briggs AH, Reed SD, Annemans L, et al
    Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial.
    J Am Coll Cardiol. 2020;75:2297-2308.
    PubMed     Abstract available

  43. DURAN EK, Aday AW, Cook NR, Buring JE, et al
    Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease.
    J Am Coll Cardiol. 2020;75:2122-2135.
    PubMed     Abstract available

    April 2020
  44. DIENER HC, Hankey GJ
    Primary and Secondary Prevention of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar.
    J Am Coll Cardiol. 2020;75:1804-1818.
    PubMed     Abstract available

  45. LOPEZ-MELGAR B, Fernandez-Friera L, Oliva B, Garcia-Ruiz JM, et al
    Short-Term Progression of Multiterritorial Subclinical Atherosclerosis.
    J Am Coll Cardiol. 2020;75:1617-1627.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Dyslipidemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.